Mirna
MI:RNA is a veterinary diagnostics company pioneering groundbreaking disease diagnosis technology. Founded in 2019, the company focuses on improving patient outcomes through innovative testing methods, including the NEMO Cardiac Health Screening and Johne’s Disease Screening. Their technology leverages serum biomarkers and AI modeling to provide early-stage disease detection, thereby enhancing veterinary practices and client engagement. With a commitment to science-based methodologies, MI:RNA has received numerous awards and grants, positioning itself as a leader in the veterinary diagnostics market.
Mirna
MI:RNA is a veterinary diagnostics company pioneering groundbreaking disease diagnosis technology. Founded in 2019, the company focuses on improving patient outcomes through innovative testing methods, including the NEMO Cardiac Health Screening and Johne’s Disease Screening. Their technology leverages serum biomarkers and AI modeling to provide early-stage disease detection, thereby enhancing veterinary practices and client engagement. With a commitment to science-based methodologies, MI:RNA has received numerous awards and grants, positioning itself as a leader in the veterinary diagnostics market.
TL;DR
Founded: 2019
Headquarters: Whitburn, United Kingdom
Sector: Veterinary diagnostics / Biotechnology
Core tech: miRNA biomarkers and AI-based tests
Recent funding: $4M Series A (Jul 2024)
Company Overview
Problem Domain
Early and accurate disease detection in animals to support veterinary decision-making and client engagement.
Founded
2019
Industry
Biotechnology
Tech Stack
Funding Track Record
4000000
Announced July 2024; raised from multiple investors across three continents.
Investor Signal
“Includes strategic and animal-health-focused investors such as NovaQuest, Kyoritsu Holdings, Animal Health Angels / VANE, Companion Fund, Gabriel Investments, Equity Gap, and Scottish Enterprise”